WHAT IS “INFLAMMATORY BOWEL DISEASE” & HOW CAN IT BE TREATED?

• Authors: Klaudia Lustyk , Jacek Sapa
• Languages of publication: EN

Abstracts

EN

Ulcerative colitis and Crohn's disease are chronic diseases of the gastrointestinal tract, which are usually grouped together as inflammatory bowel disease (IBD). Despite many researches, the etiology is still unknown, but it is believed that IBD is caused by a combination of genetic and environmental factors that interact with the immunological system. Many people worldwide (around 4 million) suffer from a form IBD and the incidence of Crohn's disease is still increasing. Aminosalicylates, corticosteroids, immunomodulators, biologic medicines reduce the inflammation, relieve symptoms, prevent flare-ups, but new, more effective drugs with smaller amount of side effects are wanted and examined.

Keywords

EN

Crohn’s disease; Etiology; Inflammatory bowel diseases; Therapy; Ulcerative colitis

Discipline

• PHARMACOLOGY: PHARMACOLOGY

• Publisher: ZOZ Ośrodek UMEA SHINODA-KURACEJO
• Journal: Medicina Internacia Revuo
• Year: 2013
• Volume: 25
• Issue: 100
• Pages: 106- 111

Contributors

author

Klaudia Lustyk

author

Jacek Sapa

• Department of Pharmacological Screening, Chair of Pharmacodynamic Faculty of Pharmacy, Medical College, Jagiellonian University, Medyczna 9, 30-688 Kraków, Poland

References

• . Cosnes, J.; Gower–Rousseau, C.; Seksik, P.; Cortot, A: Epidemiology and Natural History of Inflammatory Bowel Diseases. Gastroenterolog. 2011, 140,1785-1794.e4.
• Latella, G.; Papi, C.: Crucial steps in the natural history of inflammatory bowel disease. World J Gastroenterol. 2012, 18(29), 3790–3799.
• Koutsounas, I.; Pyleris, E.; Karantanos, P.; Barbatzas, C.: First Diagnosis of Inflammatory Bowel Disease in a 91-Year-Old Man. Case Rep Gastroenterol. 2012, 6(3), 790–796.
• Ahmad, T.; Satsangi, J.; Mcgovern, D.; Bunce, M.; Jewell, D.: The genetics of inflammatory bowel disease. Alimen-tary Pharmacology & Therapeutics 2001, 15(6), 731–748.
• Thompson, N.P.; Driscoll, R.; Pounder, R.E.; Wakefield, A.J.: Genetics versus environment in inflammatory bowel disease: results of a British twin study. Br Med J 1996, 312, 95–6.
• Halme, L.; Paavola-Sakki, P.; Turunen, U.; Lappalainen, M.; Färkkilä, M.; Kontula, K.: Family and twin studies in inflammatory bowel disease. World J Gastroenterol. 2006,12(23), 3668-3672.
• Ogura, Y.; Bonen, D.; Inohara, N.; et al: A frameshift mutation in NOD2 associated with susceptibility to Crohn’s disease. Nature 2001, 411, 603–6.
• Vatn, M.H.: Natural history and complications of IBD. Curr Gastroenterol Rep. 2009,11, 481–487.
• Monteleone, G.; Caruso, R.; Pallone, F.: Role of Smad7 in inflammatory bowel diseases. World J Gastroenterol. 2012, 18(40), 5664–5668.
• Strober, W.; Fuss, I.; Mannon, P.: The fundamental basis of inflammatory bowel disease. J Clin Invest. 2007, 117, 514–521.
• Heldin, C.H.; Miyazono, K.; Dijke, P.: TGF-beta signalling from cell membrane to nucleus through SMAD proteins. Nature. 1997, 390, 465–471.
• Monteleone, G.; Kumberova, A.; Croft, N.M.; McKenzie, C.; Steer, H.W.; MacDonald, T.T.: Blocking Smad7 restores TGF-beta1 signaling in chronic inflammatory bowel disease. J Clin Invest. 2001, 108, 601–609.
• Stober, W.; Fuss, I.; Mannon, P.: The fundamental basis of inflammatory bowel disease. J Clin Invest. 2007, 117(3), 514–521.
• Ljung, T.; Karlén, P.; Schmidt, D.; Hellström, P.M.; Lapidus, D.; Janczewska, I.; Sjöqvist, U.; Löfberg, R.: Infliximab in inflammatory bowel disease: clinical outcome in a population based cohort from Stockholm County. Gut. 2004, 53(6), 849–853.
• Hove, T.; Montfrans, C.; Peppelenbosch, M.P.; Deventer, S.J.H.: Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn's disease. Gut. 2002, 50(2), 206–211.
• Present, D.H.; Rutgeerts, P.; Targan, S.; et al.: Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 1999, 340, 1398–405.
• Barreiro-de-Acosta, M.; Lorenzo, A.; Domínguez-Mu, E.: Efficacy of adalimumab for the treatment of extraintestinal manifestations of Crohn’s disease. Rev Esp Enferm Dig. 2012, 104(9), 468- 472.
• Hinojosa del Val, J.: Old-age inflammatory bowel disease onset: A different problem? World J Gastroenterol. 2011, 17(22), 2734–2739.
• Keyashian, K.; Annunziata, M.A.; Sakuraba, A.; Hanauer, S.: Management of inflammatory bowel disease: past, present and future. Expert Review of Clinical Immunolo-gy. 2012, 8(4), 303-305.
• Thomson, A.; Gupta, M.; Freeman, H.J.: Use of the tumor necrosis factor-blockers for Crohn's disease. World J Gastroenterol. 2012, 18(35), 4823–4854.
• Műzes, G.; Molnár, B.; Sipos, F.: Regulatory T cells in inflammatory bowel diseases and colorectal cancer. World J Gastroenterol. 2012, 18(40), 5688–5694.
• Marel, S.; Majowicz, A.; Deventer, S.; Petry, H.; Hommes, D.W.; Ferreira, V.: Gene and cell therapy based treatment strategies for inflammatory bowel diseases. World J Gastrointest Pathophysiol. 2011, 2(6), 114–122.

• Document Type: article